Sanofi S.A., FR0000120578

Sanofi reports durable duvakitug data while RBC cuts Sanofi stock target to EUR 75.00

Published on 10/22/2026 at 09:32 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Sanofi's duvakitug data covered 130 patients at Week 44 on October 20, 2026. Sanofi stock costs EUR 73.09 on October 22, 2026 before October 30 results.

Pipeline data and scheduled dates

Sanofi's October 20, 2026 update covered 130 patients in a 44-week duvakitug study.
RBC cut its Sanofi target from EUR 80.00 to EUR 75.00 on October 16, 2026.
Sanofi stock was trading at EUR 73.09 at Lang & Schwarz on October 22, 2026.

Overhead flatlay of pharmaceutical objects on white surface including clear glass vials, a syringe, petri dish, test tubes, a pipette, and blue nitrile gloves — Sanofi FR0000120578 overhead flatlay of pharmaceutical vials, syringe, pipette, petri dish, and protective gloves, Illustration mit AI erstellt.

Sanofi (FR0000120578) reported Week 44 duvakitug data from 130 patients on October 20, 2026, with clinical remission reaching 47 percent at 450 mg and 58 percent at 900 mg. The update from Sanofi gives investors a fresh read on the company's inflammatory bowel disease pipeline ahead of third-quarter results.

Three dated Sanofi developments

On October 6, 2026, Sanofi published its aide-memoire for third-quarter 2026 results. On October 16, 2026, RBC cut its price target from EUR 80.00 to EUR 75.00 while keeping a Sector Perform rating, as reported by MarketScreener. Sanofi then published the duvakitug data on October 20, 2026, including a 44-week maintenance analysis.

What do the results show?

The higher dose produced a 58 percent clinical remission rate in ulcerative colitis, versus 47 percent at the lower dose. Endoscopic improvement reached 59 percent at 450 mg and 63 percent at 900 mg, while Crohn's disease endoscopic response was 41 percent and 55 percent, respectively. The study remains investigational, so these figures describe clinical development rather than an approved product.

What comes next for Sanofi?

Sanofi's investor-relations calendar schedules third-quarter 2026 results for October 30, 2026, followed by a management presentation and question-and-answer session. The company also lists a Jefferies Global Healthcare Conference appearance for November 17, 2026, according to its investor-relations calendar. The dates make the upcoming report the next major test for pipeline momentum and commercial execution.

Stock price and next catalyst

Sanofi is listed on Euronext Paris under the ticker SAN and on Nasdaq under SNY. At the latest available US close, the Nasdaq-listed American depositary receipt was USD 40.97 on October 21, 2026, while the euro quotation provides the relevant German investor perspective.

Sanofi was trading at EUR 73.09 at Lang & Schwarz on October 22, 2026 at 9:30 a.m. CEST. The October 30 results date is the next scheduled company event for investors tracking the stock.

The further course of trading is shown by the continuously updated real-time quote of Sanofi stock.